Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Parasite Immunology|May 1, 1989
Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapyM Castes, Z Moros, A Martinez, et al.
The Journal of Experimental Medicine|November 1, 1995
Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasisM Cabrera, M A Shaw, C Sharples, et al.
Experimental Dermatology|April 16, 2002
Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesionN L Diaz, O Zerpa, L V Ponce, et al.
The Journal of Infectious Diseases|January 1, 1985
HLA-linked control of predisposition to lepromatous leprosyW van Eden, N M Gonzalez, R R de Vries, et al.
The American Journal of Tropical Medicine and Hygiene|November 1, 1994
Coexistence of two species of Leishmania in the digestive tract of the vector Lutzomyia ovallesiM Barrios, N Rodriguez, D M Feliciangeli, et al.
Acta Cientifica Venezolana|March 20, 2002
The molecular epidemiology of tuberculosis in Caracas, Venezuela, with IS6110 DNA fingerprintingS Toro, R Armengol, J Convit, et al.
Tissue Antigens|July 1, 1984
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan populationT H Ottenhoff, N M Gonzalez, R R de Vries, et al.
Medicina Cutanea Ibero-Latino-Americana|January 1, 1977
[A clinical constelation in disuse: vitiligo, mastocytosis of the bone marrow, circulating heparinoid, chronic leg ulcer, hypoalbuminemia, ulcerative colitis and hepatic fibrosis]M Goihman Yahr, C Goldstein, Y González, et al.
International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association|December 1, 1994
A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapyE Rada, M Ulrich, N Aranzazu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2015
Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapyJ Convit, H Montesinos, H Oviedo, et al.
Pageof 10